Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series

Table 1 Clinical characteristics of the patients

Patient	Sex	CAG	AO Motoric	AO Psychic	Duration	TFC	IS %	Rigidity	Swallowing problems
Case 1	M	22/46	28	22	11	2	20	++	+++
Case 2	F	20/54	37	ND	6	5	70	+	-
Case 3*	M	17/48	23	23	8	3	40	++	++
Case 3*	M	17/48	23	23	12	2	30	++	+++
Case 4	M	19/48	33	ND	11	4	40	+++	++
Case 5	M	17/43	50	45	6	3	40	++	++
Case 6	F	25/52	31	ND	10	3	40	++	++
Case 7	F	17/50	28	26	7	6	70	+	-
Case 8	M	17/50	30	30	11	3	30	+++	+++

Clinical characteristics of the patients. AO = age of onset, TFC = Total functional capacity (UHDRS), IS = Independence score (UHDRS), CAG = CAG-ranges (low/high); Intensity: - = none, + = mild, ++ = moderate, +++ = severe. ND = no data. One patient (*) was treated twice with an increased dose of valproic acid within a 4 year period, see text.

ISSN: 1471-2377